Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-920-201 Fabry Disease Gene Therapy Phase I/II
2024-512695-34-00Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Jul 2024
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of isaralgagene civaparvovec in Fabry disease (FD), sponsored by Sangamo Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs) and Safety labs and assessments. Started Jul 2024; status: completed.
02
Drugs
isaralgagene civaparvovec
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2024-512695-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512695-34-00.